## Markku Sainio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3901461/publications.pdf

Version: 2024-02-01

51	1,259	19	34
papers	citations	h-index	g-index
51	51	51	1211
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Current Opinion in Cell Biology, 1997, 9, 659-666.	2.6	191
2	High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Human Molecular Genetics, 2001, 10, 271-282.	1.4	147
3	Multiple schwannomas: schwannomatosis or neurofibromatosis type 2?. Journal of Neurosurgery, 1998, 89, 36-41.	0.9	81
4	Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. Journal of Neurosurgery, 1997, 87, 610-614.	0.9	73
5	Stability of vocational outcome in adulthood after moderate to severe preschool brain injury. Journal of the International Neuropsychological Society, 2004, 10, 719-723.	1.2	50
6	Chronic solvent-induced encephalopathy: European consensus of neuropsychological characteristics, assessment, and guidelines for diagnostics. NeuroToxicology, 2012, 33, 710-726.	1.4	49
7	Structure-function relationships in the ezrin family and the effect of tumor-associated point mutations in neurofibromatosis 2 protein. BBA - Proteins and Proteomics, 1998, 1387, 1-16.	2.1	48
8	Solvent-related health effects among construction painters with decreasing exposure. American Journal of Industrial Medicine, 2004, 46, 627-636.	1.0	39
9	Prevalence of various environmental intolerances in a Swedish and Finnish general population. Environmental Research, 2018, 161, 220-228.	3.7	36
10	Cervical and lumbar pain and radiological degeneration among fighter pilots: a systematic review and meta-analysis. Occupational and Environmental Medicine, 2015, 72, 145-150.	1.3	35
11	Proliferative Potential of Sporadic and Neurofibromatosis 2-Associated Schwannomas as Studied by MIB-1 (Ki-67) and PCNA Labeling. Journal of Neuropathology and Experimental Neurology, 1995, 54, 776-782.	0.9	31
12	Identification of genetic aberrations on chromosome 22 outside theNF2locus in schwannomatosis and neurofibromatosis type 2. Human Mutation, 2005, 26, 540-549.	1.1	29
13	Frequent loss of heterozygosity at 6q in pheochromocytoma. Human Pathology, 2006, 37, 749-754.	1.1	29
14	Chromosome 22q alterations and expression of the NF2 gene product, merlin, in gastrointestinal stromal tumors. Human Pathology, 2003, 34, 872-879.	1.1	26
15	Symptom screening in detection of occupational solvent-related encephalopathy. International Archives of Occupational and Environmental Health, 2009, 82, 343-355.	1.1	26
16	Occupational chronic solvent encephalopathy in Finland 1995–2007: incidence and exposure. International Archives of Occupational and Environmental Health, 2010, 83, 703-712.	1.1	26
17	Symptoms of chronic solvent encephalopathy: Euroquest questionnaire study. NeuroToxicology, 2009, 30, 1187-1194.	1.4	24
18	Memory Performance Profile in Occupational Chronic Solvent Encephalopathy Suggests Working Memory Dysfunction. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 1307-1326.	0.8	21

#	Article	IF	CITATIONS
19	Loss of Heterozygosity at 6q Is Frequent and Concurrent with 3p Loss in Sporadic and Familial Capillary Hemangioblastomas. Journal of Neuropathology and Experimental Neurology, 2004, 63, 1072-1079.	0.9	20
20	Magnetic resonance imaging in occupational chronic solvent encephalopathy. International Archives of Occupational and Environmental Health, 2009, 82, 595-602.	1.1	20
21	Recurrent DNA sequence copy losses on chromosomal arm 6q in capillary hemangioblastoma. Cancer Genetics and Cytogenetics, 2002, 133, 174-178.	1.0	19
22	Detecting chronic solvent encephalopathy in occupations at risk. NeuroToxicology, 2012, 33, 734-741.	1.4	19
23	Neurotoxicity of solvents. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 131, 93-110.	1.0	19
24	Decreased work ability associated to indoor air problems – An intervention (RCT) to promote health behavior. NeuroToxicology, 2015, 49, 59-67.	1.4	18
25	Building-Related Environmental Intolerance and Associated Health in the General Population. International Journal of Environmental Research and Public Health, 2018, 15, 2047.	1.2	16
26	Environmental Intolerance, Symptoms and Disability Among Fertile-Aged Women. International Journal of Environmental Research and Public Health, 2018, 15, 293.	1.2	15
27	Colour vision defects in occupational chronic solvent encephalopathy. Human and Experimental Toxicology, 2007, 26, 375-384.	1.1	14
28	Genomic structure of the human ezrin gene. Human Genetics, 1998, 103, 662-665.	1.8	12
29	Annoyance, perception, and physiological effects of wind turbine infrasound. Journal of the Acoustical Society of America, 2021, 149, 2238-2248.	0.5	12
30	Clinical Characteristics of Disability in Patients with Indoor Air–Related Environmental Intolerance. Safety and Health at Work, 2019, 10, 362-369.	0.3	11
31	Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. Oncology Reports, 2002, 9, 955.	1.2	9
32	Effects of long-term occupational solvent exposure on contrast sensitivity and performance in visual search. Environmental Toxicology and Pharmacology, 2005, 19, 497-504.	2.0	9
33	Cost of detecting a chronic solvent encephalopathy case by screening. NeuroToxicology, 2014, 45, 253-259.	1.4	8
34	Healthy people in healthy premises: the Finnish Indoor Air and Health Programme 2018–2028. Clinical and Translational Allergy, 2020, 10, 4.	1.4	8
35	P300 of auditory event related potentials in occupational chronic solvent encephalopathy. NeuroToxicology, 2007, 28, 1230-1236.	1.4	7
36	Attention-Deficit/Hyperactivity Disorder and Fatal Accidents in Aviation Medicine. Aerospace Medicine and Human Performance, 2017, 88, 871-875.	0.2	7

#	Article	IF	CITATIONS
37	Health-related quality among life of employees with persistent nonspecific indoor-air-associated health complaints. Journal of Psychosomatic Research, 2019, 122, 112-120.	1.2	7
38	Anosmia in association with occupational use of a waterproof coating chemical. Occupational Medicine, 2005, 55, 142-144.	0.8	6
39	Visual search and eye movements in patients with chronic solvent-induced toxic encephalopathy. NeuroToxicology, 2006, 27, 1013-1023.	1.4	5
40	Multimodal event-related potentials in occupational chronic solvent encephalopathy. NeuroToxicology, 2012, 33, 703-709.	1.4	5
41	Comparing cognitive-behavioural psychotherapy and psychoeducation for non-specific symptoms associated with indoor air: a randomised control trial protocol. BMJ Open, 2016, 6, e011003.	0.8	5
42	Solvent exposed occupations and risk of Parkinson disease in Finland. Clinical Parkinsonism & Related Disorders, 2021, 4, 100092.	0.5	5
43	Chronic Solvent induced Encephalopathy: A step forward. NeuroToxicology, 2012, 33, 897-901.	1.4	4
44	Solvent-induced encephalopathy in the Netherlands and Finland. Occupational Medicine, 2015, 65, 609-611.	0.8	4
45	Work ability score of solvent-exposed workers. International Archives of Occupational and Environmental Health, 2018, 91, 559-569.	1.1	4
46	Psychosocial treatments for employees with non-specific and persistent physical symptoms associated with indoor air: A randomised controlled trial with a one-year follow-up. Journal of Psychosomatic Research, 2020, 131, 109962.	1.2	4
47	Prevalence of environmental annoyance in a Swedish and Finnish general population: Impact of everyday exposures on affect and behavior. Journal of Environmental Psychology, 2018, 56, 84-90.	2.3	3
48	Reply to Letter to the Editor: Cognitive therapy in Sick Building Syndrome: Myths, beliefs or evidence. NeuroToxicology, 2016, 52, 186-187.	1.4	2
49	Limitations of periodical health examinations in detecting occupational chronic solvent encephalopathy. Occupational and Environmental Medicine, 2019, 76, 688-693.	1.3	1
50	10th Congress of International Neurotoxicology Association. Human and Experimental Toxicology, 2007, 26, 147-148.	1.1	0
51	1713aâ€Why isn't chronic solvent encephalopathy detected in periodical occupational health examinations. , 2018, , .		0